Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

A legfontosabb adatok

Ki végzi
Abramson Cancer Center at Penn Medicine
Hol
Philadelphia (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
5 fő vett részt
Kezdés
2022. jan. 24.
Befejezés
2024. ápr. 25.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Axitinib 5 MG
  • Hydroxychloroquine Pill
  • trans arterial chemoembolization
A regiszteradat frissítve
2024. április 26.
Miért állt le
failure to accrue

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18 years or more
  • Pathologically-verified diagnosis of colorectal adenocarcinoma
  • Measurable metastasis to liver with at least one dimension ≥ 1.0 cm
  • Liver dominant metastases as judged by multidisciplinary team consensus review of cross-sectional imaging of the chest, abdomen and pelvis
  • At least 2 weeks must have elapsed from the last dose of chemotherapy before starting HCQ and at least 4 weeks must have elapsed from the last dose of VEGF/VEGFR therapy prior to starting axitinib
  • Subjects must be at least 2 weeks beyond prior radiotherapy or surgery, and have recovered from all therapy associated toxicities
  • Eastern Cooperative Oncology Group (ECOG) Performance status must be 0-1 (see Appendix II)
  • Absolute granulocyte count > 1,500/ul, platelet count > 75,000/ul, International Normalized Ratio (INR) < 1.6
  • Serum creatinine < 2.0 mg/dl; serum bilirubin < 2.0 mg/dl
  • Urine protein:creatinine ratio < 1 or 24-hour urine protein < 1 gm/day
  • Liver function Child-Pugh A
  • Competent and willing to provide informed consent
  • Patients of reproductive potential agree to use approved contraceptive methods per section 5.4

Ki nem vehet részt

  • Prior hepatic arterial infusion chemotherapy or hepatic radiation therapy. Prior surgical resection or ablation of liver metastases is acceptable
  • No more than two prior lines of systemic chemotherapy
  • Contraindications to angiography and selective visceral catheterization:; severe allergy or intolerance to contrast media not controllable with prophylaxis; bleeding diathesis not correctable by usual forms of therapy; severe peripheral vascular disease precluding catheterization
  • Known allergic reactions to irinotecan, HCQ or axitinib
  • Allergy to contrast not mitigated by usual prophylaxis
  • Serious infection requiring intravenous therapy
  • Known retinal disease
  • Poorly controlled hypertension, defined as a blood pressure > 150/100 at the time of enrollment. Patients with a preexisting hypertension must be on a stable anti-hypertensive regimen
  • History of abdominal fistula, gastrointestinal perforation, or serious non-healing wounds, ulcers, or bone fractures
  • Known New York Heart Association class II or greater congestive heart failure (defined as symptoms of fatigue, dyspnea, or other symptoms with ordinary physical activity)
  • Known untreated brain metastases. History of treated metastases off steroids allowed
  • Contraindications to hepatic artery embolization:; high risk of hepatic failure, indicated by the constellation of greater than 50% liver replacement by tumor, lactate dehydrogenase (LDH) >425 mU/ml, aspartate aminotransferase (AST) >100mU/ml. and bilirubin >2 mg/dl; tumor volume >75% of total liver volume; portal vein occlusion without hepatopetal collateral flow demonstrated by angiography; or portal hypertension with hepatofugal flow; hepatic encephalopathy
  • Pregnancy or lactation

Helyszínek itt: Egyesült Államok

  • Abramson Cancer CenterPhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves progression-free survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both response and PFS following TACE.

A vizsgálat csoportja

  • TACE+axitinib+HCQA vizsgált kezelés

    2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.

    Kezelés: Axitinib 5 MG, Hydroxychloroquine Pill és trans arterial chemoembolization

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 1B Study of Hepatic Chemoembolization Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum
A regiszteradat frissítve
2024. április 26.